Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 SEOM guideline for the treatment of malignant glioma.

Literature DB >> 22721801

SEOM guideline for the treatment of malignant glioma.

Alfonso Berrocal¹, Miguel Gil, Óscar Gallego, Carmen Balaña, Pedro Pérez Segura, Jesús García-Mata, Gaspar Reynes.

Abstract

High-grade gliomas are an infrequent disease diagnosed usually in the fifth or sixth decade. Careful histopathological diagnosis is essential because tumour grade and type condition the treatment. Magnetic resonance with gadolinium is considered the standard radiologic exploration and should be followed by tissue sampling. Treatment of these patients should be decided in a multidisciplinary committee. Surgery, radiotherapy and chemotherapy are the basis of patients' treatment, with the best results obtained when the three of them can be used.

Entities: Chemical Disease Species

Mesh：

Year: 2012 PMID： 22721801 DOI： 10.1007/s12094-012-0839-6

Source DB: PubMed Journal: Clin Transl Oncol ISSN： 1699-048X Impact factor: 3.405

22 in total

1. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544

2. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.

Authors: Alba A Brandes; Linda Nicolardi; Alicia Tosoni; Marina Gardiman; Paolo Iuzzolino; Claudio Ghimenton; Michele Reni; Antonino Rotilio; Guido Sotti; Mario Ermani
Journal: Neuro Oncol Date: 2006-05-24 Impact factor: 12.300

3. Temozolomide chemotherapy in recurrent oligodendroglioma.

Authors: M J van den Bent; F Keime-Guibert; A A Brandes; M J Taphoorn; J M Kros; F A Eskens; A F Carpentier
Journal: Neurology Date: 2001-07-24 Impact factor: 9.910

4. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.

Authors: M D Prados; C Scott; W J Curran; D F Nelson; S Leibel; S Kramer
Journal: J Clin Oncol Date: 1999-11 Impact factor: 44.544

5. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.

Authors: V A Levin; P Silver; J Hannigan; W M Wara; P H Gutin; R L Davis; C B Wilson
Journal: Int J Radiat Oncol Biol Phys Date: 1990-02 Impact factor: 7.038

6. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.

Authors: François Ducray; Monica Sierra del Rio; Catherine Carpentier; Dimitri Psimaras; Ahmed Idbaih; Caroline Dehais; Gentian Kaloshi; Karima Mokhtari; Sophie Taillibert; Florence Laigle-Donadey; Antonio Omuro; Marc Sanson; Jean-Yves Delattre; Khê Hoang-Xuan
Journal: J Neurooncol Date: 2010-06-17 Impact factor: 4.130

7. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.

Authors: K E Wallner; J H Galicich; G Krol; E Arbit; M G Malkin
Journal: Int J Radiat Oncol Biol Phys Date: 1989-06 Impact factor: 7.038

8. Temozolomide as second-line chemotherapy for relapsed gliomas.

Authors: S Trent; A Kong; S C Short; D Traish; S Ashley; A Dowe; F Hines; M Brada
Journal: J Neurooncol Date: 2002-05 Impact factor: 4.130

9. Grading of astrocytomas. A simple and reproducible method.

Authors: C Daumas-Duport; B Scheithauer; J O'Fallon; P Kelly
Journal: Cancer Date: 1988-11-15 Impact factor: 6.860

10. Radiotherapy for glioblastoma in the elderly.

Authors: Florence Keime-Guibert; Olivier Chinot; Luc Taillandier; Stéphanie Cartalat-Carel; Marc Frenay; Guy Kantor; Jean-Sébastien Guillamo; Eric Jadaud; Philippe Colin; Pierre-Yves Bondiau; Philippe Meneï; Hugues Loiseau; Valérie Bernier; Jérôme Honnorat; Maryline Barrié; Karima Mokhtari; Jean-Jacques Mazeron; Anne Bissery; Jean-Yves Delattre
Journal: N Engl J Med Date: 2007-04-12 Impact factor: 91.245

5 in total

SEOM guideline for the treatment of malignant glioma.

1. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

2. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.

3. Temozolomide chemotherapy in recurrent oligodendroglioma.

4. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.

5. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.

6. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.

7. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.

8. Temozolomide as second-line chemotherapy for relapsed gliomas.

9. Grading of astrocytomas. A simple and reproducible method.

10. Radiotherapy for glioblastoma in the elderly.

1. SEOM clinical guidelines: a consolidated project.

Review 2. Quality appraisal of clinical practice guidelines on glioma.

3. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?

4. Synergistic anti-glioma effect of a coloaded nano-drug delivery system.

5. SEOM clinical guidelines for anaplastic gliomas (2017).